SECTM1
gene geneOn this page
Also known as K12
Summary
SECTM1 (secreted and transmembrane 1, HGNC:10707) is a protein-coding gene on chromosome 17q25.3, encoding Secreted and transmembrane protein 1 (Q8WVN6). May be involved in thymocyte signaling.
This gene encodes a transmembrane and secreted protein with characteristics of a type 1a transmembrane protein. It is found in a perinuclear Golgi-like pattern and thought to be involved in hematopoietic and/or immune system processes.
Source: NCBI Gene 6398 — RefSeq curated summary.
At a glance
- GWAS associations: 2
- Clinical variants (ClinVar): 51 total
- MANE Select transcript:
NM_003004
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:10707 |
| Approved symbol | SECTM1 |
| Name | secreted and transmembrane 1 |
| Location | 17q25.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | K12 |
| Ensembl gene | ENSG00000141574 |
| Ensembl biotype | protein_coding |
| OMIM | 602602 |
| Entrez | 6398 |
Gene structure
Transcript identifiers
Ensembl transcripts: 19 — 18 protein_coding, 1 nonsense_mediated_decay
ENST00000269389, ENST00000580437, ENST00000581691, ENST00000581864, ENST00000581954, ENST00000582290, ENST00000582563, ENST00000583093, ENST00000856789, ENST00000856790, ENST00000856791, ENST00000856792, ENST00000856793, ENST00000856794, ENST00000856795, ENST00000856796, ENST00000856797, ENST00000927831, ENST00000958226
RefSeq mRNA: 1 — MANE Select: NM_003004
NM_003004
CCDS: CCDS11808
Canonical transcript exons
ENST00000269389 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000949847 | 82324582 | 82324890 |
| ENSE00001243873 | 82321024 | 82322370 |
| ENSE00001309259 | 82327147 | 82327292 |
| ENSE00002704588 | 82333700 | 82333766 |
| ENSE00003660290 | 82322878 | 82323011 |
Expression profiles
Bgee: expression breadth ubiquitous, 229 present calls, max score 98.03.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.2013 / max 933.6635, expressed in 1044 samples.
FANTOM5 promoters (5 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 168978 | 6.2072 | 681 |
| 168979 | 5.9650 | 868 |
| 168981 | 0.8516 | 333 |
| 168980 | 0.0934 | 47 |
| 168977 | 0.0840 | 28 |
Top tissues by expression
283 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| monocyte | CL:0000576 | 98.03 | gold quality |
| mononuclear cell | CL:0000842 | 98.00 | gold quality |
| leukocyte | CL:0000738 | 97.92 | gold quality |
| granulocyte | CL:0000094 | 97.18 | gold quality |
| blood | UBERON:0000178 | 96.20 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 94.99 | gold quality |
| ileal mucosa | UBERON:0000331 | 94.14 | gold quality |
| jejunal mucosa | UBERON:0000399 | 93.25 | gold quality |
| duodenum | UBERON:0002114 | 93.23 | gold quality |
| spleen | UBERON:0002106 | 90.91 | gold quality |
| vermiform appendix | UBERON:0001154 | 90.75 | gold quality |
| decidua | UBERON:0002450 | 88.58 | gold quality |
| small intestine | UBERON:0002108 | 88.56 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 88.40 | gold quality |
| transverse colon | UBERON:0001157 | 87.87 | gold quality |
| rectum | UBERON:0001052 | 87.77 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 87.55 | gold quality |
| minor salivary gland | UBERON:0001830 | 87.43 | gold quality |
| caecum | UBERON:0001153 | 87.08 | gold quality |
| pancreatic ductal cell | CL:0002079 | 86.41 | silver quality |
| gall bladder | UBERON:0002110 | 86.20 | gold quality |
| mouth mucosa | UBERON:0003729 | 86.10 | gold quality |
| omental fat pad | UBERON:0010414 | 85.79 | gold quality |
| peritoneum | UBERON:0002358 | 85.73 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 85.69 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 85.65 | gold quality |
| intestine | UBERON:0000160 | 85.64 | gold quality |
| colon | UBERON:0001155 | 85.62 | gold quality |
| large intestine | UBERON:0000059 | 85.34 | gold quality |
| adipose tissue of abdominal region | UBERON:0007808 | 85.06 | gold quality |
Single-cell (SCXA)
Detected in 4 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 12.31 |
| E-MTAB-8498 | yes | 10.41 |
| E-GEOD-99795 | no | 78.22 |
| E-MTAB-4850 | no | 43.01 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): NFKB, STAT3
miRNA regulators (miRDB)
16 targeting SECTM1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4283 | 100.00 | 66.42 | 2097 |
| HSA-MIR-6793-5P | 99.97 | 65.95 | 758 |
| HSA-MIR-3942-3P | 99.57 | 69.03 | 2854 |
| HSA-MIR-5683 | 99.36 | 68.59 | 2083 |
| HSA-MIR-4260 | 98.78 | 65.37 | 848 |
| HSA-MIR-1227-5P | 98.65 | 65.32 | 1549 |
| HSA-MIR-890 | 97.47 | 68.67 | 982 |
| HSA-MIR-134-3P | 96.83 | 66.22 | 1001 |
| HSA-MIR-1226-5P | 96.50 | 65.28 | 643 |
| HSA-MIR-6874-5P | 95.73 | 64.94 | 545 |
| HSA-MIR-103B | 95.51 | 66.85 | 441 |
| HSA-MIR-4633-3P | 93.85 | 63.56 | 534 |
| HSA-MIR-6500-5P | 93.85 | 63.64 | 522 |
| HSA-MIR-4785 | 88.53 | 62.71 | 63 |
| HSA-MIR-658 | 88.20 | 67.03 | 178 |
| HSA-MIR-4783-3P | 73.56 | 61.87 | 82 |
Literature-anchored findings (GeneRIF, showing 4)
- level of SECTM1 expression is likely to be a key factor in innate immune responses and in the immune tolerance of cancerous cells (PMID:21749909)
- CD7 is present on monocytes and tumor macrophages and its ligand, SECTM1, is frequently expressed in corresponding melanoma tissues (PMID:24157461)
- SECTM1 secreted from bone marrow stromal cells may interact with CD7 to influence GM-CSF expression in leukemic cells. (PMID:24211252)
- SECTM1 promotes the development of glioblastoma and mesenchymal transition by regulating the TGFbeta1/Smad signaling pathway. (PMID:38164182)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Sectm1a | ENSMUSG00000025165 |
| mus_musculus | Sectm1b | ENSMUSG00000039364 |
| rattus_norvegicus | Sectm1a | ENSRNOG00000036672 |
| rattus_norvegicus | Sectm1b | ENSRNOG00000036673 |
Protein
Protein identifiers
Secreted and transmembrane protein 1 — Q8WVN6 (reviewed: Q8WVN6)
Alternative names: Protein K-12
All UniProt accessions (8): Q8WVN6, J3KS40, J3KSN0, J3KTR4, J3QKK2, J3QQU6, J3QR99, J3QRU5
UniProt curated annotations — full annotation on UniProt →
Function. May be involved in thymocyte signaling.
Subunit / interactions. Interacts with CD7.
Subcellular location. Cell membrane. Secreted.
Tissue specificity. Detected at the highest levels in peripheral blood leukocytes and breast cancer cell lines. Found in leukocytes of the myeloid lineage, with the strongest expression observed in granulocytes and no detectable expression in lymphocytes. Expressed in thymic epithelial cells and fibroblasts.
Induction. By IFNG/IFN-gamma (at protein level).
Similarity. Belongs to the SECTM family.
RefSeq proteins (1): NP_002995* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR013783 | Ig-like_fold | Homologous_superfamily |
| IPR033231 | SECTM1 | Family |
UniProt features (8 total): topological domain 2, signal peptide 1, chain 1, transmembrane region 1, glycosylation site 1, disulfide bond 1, sequence conflict 1
Structure
Experimental structures (PDB)
1 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 12NP | X-RAY DIFFRACTION | 2.4 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q8WVN6-F1 | 75.00 | 0.43 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Disulfide bonds (1): 38–55
Glycosylation sites (1): 56
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 256 (showing top):
WALLACE_PROSTATE_CANCER_RACE_UP, GOBP_POSITIVE_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, BENPORATH_ES_WITH_H3K27ME3, GOBP_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION_INVOLVED_IN_IMMUNE_RESPONSE, MODULE_45, MODULE_418, GOZGIT_ESR1_TARGETS_DN, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_REGULATION_OF_IMMUNE_RESPONSE, RICKMAN_METASTASIS_DN, GOBP_LYMPHOCYTE_MEDIATED_IMMUNITY, FOSTER_TOLERANT_MACROPHAGE_UP
GO Biological Process (6): positive regulation of T cell cytokine production (GO:0002726), immune response (GO:0006955), mesoderm development (GO:0007498), positive regulation of canonical NF-kappaB signal transduction (GO:0043123), signal transduction (GO:0007165), interleukin-2-mediated signaling pathway (GO:0038110)
GO Molecular Function (3): cytokine activity (GO:0005125), receptor ligand activity (GO:0048018), protein binding (GO:0005515)
GO Cellular Component (6): obsolete extracellular space (GO:0005615), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), membrane (GO:0016020), extracellular exosome (GO:0070062), extracellular region (GO:0005576)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 2 |
| T cell cytokine production | 1 |
| positive regulation of T cell mediated immunity | 1 |
| positive regulation of cytokine production involved in immune response | 1 |
| regulation of T cell cytokine production | 1 |
| immune system process | 1 |
| response to stimulus | 1 |
| tissue development | 1 |
| canonical NF-kappaB signal transduction | 1 |
| regulation of canonical NF-kappaB signal transduction | 1 |
| positive regulation of intracellular signal transduction | 1 |
| cell communication | 1 |
| cellular process | 1 |
| signaling | 1 |
| regulation of cellular process | 1 |
| cellular response to stimulus | 1 |
| cytokine-mediated signaling pathway | 1 |
| cellular response to interleukin-2 | 1 |
| receptor ligand activity | 1 |
| signaling receptor binding | 1 |
| signal transduction | 1 |
| signaling receptor activator activity | 1 |
| binding | 1 |
| cytoplasm | 1 |
| endomembrane system | 1 |
| intracellular membrane-bounded organelle | 1 |
| membrane | 1 |
| cell periphery | 1 |
| extracellular vesicle | 1 |
Protein interactions and networks
STRING
508 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| SECTM1 | CD7 | P09564 | 951 |
| SECTM1 | TEX19 | Q8NA77 | 462 |
| SECTM1 | KRT12 | Q99456 | 399 |
| SECTM1 | KRT33B | Q14525 | 377 |
| SECTM1 | ZNF664 | Q8N3J9 | 374 |
| SECTM1 | KRT34 | O76011 | 364 |
| SECTM1 | ZMYND15 | Q9H091 | 327 |
| SECTM1 | IGFLR1 | Q9H665 | 322 |
| SECTM1 | PLEKHA4 | Q9H4M7 | 320 |
| SECTM1 | HERC2 | O95714 | 318 |
| SECTM1 | UBD | O15205 | 317 |
| SECTM1 | GPR162 | Q16538 | 311 |
| SECTM1 | IPP | Q9Y573 | 307 |
| SECTM1 | SINHCAF | Q9NP50 | 305 |
| SECTM1 | TMIGD1 | Q6UXZ0 | 303 |
IntAct
14 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| ANKRD46 | SECTM1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| EMP3 | SECTM1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CLEC4A | SEMA7A | psi-mi:“MI:0914”(association) | 0.530 |
| NLRP12 | SECTM1 | psi-mi:“MI:0915”(physical association) | 0.370 |
| SECTM1 | GAPDHS | psi-mi:“MI:0914”(association) | 0.350 |
| CLEC4A | psi-mi:“MI:0914”(association) | 0.350 | |
| CD7 | PIK3R2 | psi-mi:“MI:0914”(association) | 0.350 |
| RYK | DUSP14 | psi-mi:“MI:0914”(association) | 0.350 |
| EMP3 | SECTM1 | psi-mi:“MI:0915”(physical association) | 0.000 |
| ANKRD46 | SECTM1 | psi-mi:“MI:0915”(physical association) | 0.000 |
| Y0062 | SECTM1 | psi-mi:“MI:0915”(physical association) | 0.000 |
BioGRID (19): ALDH1B1 (Affinity Capture-MS), BCLAF1 (Affinity Capture-MS), CANX (Affinity Capture-MS), DDX60L (Affinity Capture-MS), DNAJB11 (Affinity Capture-MS), NUP210 (Affinity Capture-MS), PDIA6 (Affinity Capture-MS), SDF2 (Affinity Capture-MS), SDF2L1 (Affinity Capture-MS), SECTM1 (Affinity Capture-MS), SECTM1 (Affinity Capture-MS), EMP3 (Two-hybrid), ANKRD46 (Two-hybrid), GAPDHS (Affinity Capture-MS), CCDC109B (Affinity Capture-MS)
ESM2 similar proteins: A2A7V7, A2TGX5, A5D7B2, O88875, O95866, O95944, O95971, O95998, P22273, Q01114, Q02242, Q1ERP8, Q2LA85, Q2TB54, Q3B8P2, Q3LRV9, Q3U497, Q566E6, Q5R770, Q5T2D2, Q60513, Q63994, Q6DKI7, Q6MG59, Q6QUN5, Q6SJQ0, Q6SJQ5, Q6SJQ7, Q6TYI6, Q6UXG3, Q6UXN2, Q7L513, Q7TSN2, Q86YW5, Q8K558, Q8N109, Q8NHJ6, Q8NHK3, Q8TDQ1, Q8VCH2
Diamond homologs: Q8WVN6, Q921W8, Q9JL59
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
51 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 36 |
| Likely benign | 8 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1155 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 17:82322371:C:CC | acceptor_gain | 1.0000 |
| 17:82322873:CCTAC:C | donor_loss | 1.0000 |
| 17:82322875:TA:T | donor_loss | 1.0000 |
| 17:82322876:A:AT | donor_loss | 1.0000 |
| 17:82322877:C:CA | donor_loss | 1.0000 |
| 17:82322879:T:TA | donor_gain | 1.0000 |
| 17:82324578:TCA:T | donor_loss | 1.0000 |
| 17:82324579:CA:C | donor_loss | 1.0000 |
| 17:82324581:C:G | donor_loss | 1.0000 |
| 17:82324583:TGAA:T | donor_gain | 1.0000 |
| 17:82327289:CTCC:C | acceptor_gain | 1.0000 |
| 17:82322368:CTT:C | acceptor_gain | 0.9900 |
| 17:82322371:C:A | acceptor_loss | 0.9900 |
| 17:82322876:ACCT:A | donor_gain | 0.9900 |
| 17:82322876:ACCTC:A | donor_gain | 0.9900 |
| 17:82322877:CCTC:C | donor_gain | 0.9900 |
| 17:82322877:CCTCC:C | donor_gain | 0.9900 |
| 17:82322880:C:A | donor_gain | 0.9900 |
| 17:82323106:C:CA | donor_gain | 0.9900 |
| 17:82324581:CCTG:C | donor_gain | 0.9900 |
| 17:82324582:CTGA:C | donor_gain | 0.9900 |
| 17:82324590:T:TA | donor_gain | 0.9900 |
| 17:82324886:CCAGC:C | acceptor_gain | 0.9900 |
| 17:82324887:CAGC:C | acceptor_gain | 0.9900 |
| 17:82324887:CAGCC:C | acceptor_gain | 0.9900 |
| 17:82324890:CCT:C | acceptor_loss | 0.9900 |
| 17:82324891:C:CC | acceptor_gain | 0.9900 |
| 17:82324891:CT:C | acceptor_loss | 0.9900 |
| 17:82324892:T:C | acceptor_loss | 0.9900 |
| 17:82324900:C:CT | acceptor_gain | 0.9900 |
AlphaMissense
1595 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 17:82324634:C:A | W117C | 0.998 |
| 17:82324634:C:G | W117C | 0.998 |
| 17:82324636:A:G | W117R | 0.996 |
| 17:82324636:A:T | W117R | 0.996 |
| 17:82324751:G:C | F78L | 0.994 |
| 17:82324751:G:T | F78L | 0.994 |
| 17:82324753:A:G | F78L | 0.994 |
| 17:82324821:C:G | C55S | 0.994 |
| 17:82324822:A:T | C55S | 0.994 |
| 17:82324680:A:G | L102P | 0.993 |
| 17:82324712:C:A | W91C | 0.993 |
| 17:82324712:C:G | W91C | 0.993 |
| 17:82324821:C:T | C55Y | 0.992 |
| 17:82324752:A:G | F78S | 0.991 |
| 17:82324822:A:G | C55R | 0.991 |
| 17:82324707:A:G | L93P | 0.989 |
| 17:82324635:C:G | W117S | 0.988 |
| 17:82324629:A:G | L119P | 0.987 |
| 17:82324642:A:C | Y115D | 0.987 |
| 17:82324872:C:G | C38S | 0.987 |
| 17:82324873:A:T | C38S | 0.987 |
| 17:82324714:A:G | W91R | 0.986 |
| 17:82324714:A:T | W91R | 0.986 |
| 17:82324820:G:C | C55W | 0.986 |
| 17:82324873:A:G | C38R | 0.986 |
| 17:82324648:C:A | G113W | 0.985 |
| 17:82324794:A:T | V64D | 0.985 |
| 17:82324872:C:T | C38Y | 0.985 |
| 17:82324616:C:A | Q123H | 0.984 |
| 17:82324616:C:G | Q123H | 0.984 |
dbSNP variants (sampled 300 via entrez): RS1000048831 (17:82328139 T>A,G), RS1000262018 (17:82331010 C>G), RS1000293046 (17:82330820 G>A), RS1000504797 (17:82334501 C>T), RS1000625091 (17:82335321 T>C), RS1000636898 (17:82329675 G>A,T), RS1000699665 (17:82330891 C>A,G,T), RS1000717352 (17:82326090 C>A), RS1000765462 (17:82324715 G>A), RS1000773316 (17:82330682 G>A,C), RS1001154228 (17:82334134 C>T), RS1001251371 (17:82333343 CAA>C), RS1001324787 (17:82333147 C>A,T), RS1001522182 (17:82334316 G>A), RS1001589682 (17:82326263 G>A,C,T)
Disease associations
OMIM: gene MIM:602602 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
2 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST006585_879 | Blood protein levels | 2.000000e-26 |
| GCST90002394_416 | Monocyte percentage of white cells | 8.000000e-18 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0007989 | monocyte percentage of leukocytes |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
48 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | decreases expression, increases expression | 4 |
| Benzo(a)pyrene | affects methylation, increases expression, increases methylation | 3 |
| Tetrachlorodibenzodioxin | increases expression | 3 |
| Particulate Matter | decreases expression, increases abundance, increases expression | 3 |
| (+)-JQ1 compound | decreases expression | 2 |
| Arsenic Trioxide | decreases expression, increases expression | 2 |
| Estradiol | affects cotreatment, decreases expression, increases expression | 2 |
| Nickel | decreases expression, increases expression | 2 |
| Tobacco Smoke Pollution | decreases expression, increases expression | 2 |
| GSK-J4 | increases expression | 1 |
| OTX015 | decreases expression | 1 |
| mivebresib | decreases expression | 1 |
| dicrotophos | decreases expression | 1 |
| chloroacetaldehyde | increases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| 2,5,2’,5’-tetrachlorobiphenyl | decreases expression | 1 |
| 2-methyl-4-isothiazolin-3-one | decreases expression | 1 |
| kojic acid | decreases expression | 1 |
| tris(2-butoxyethyl) phosphate | affects expression | 1 |
| perfluorooctanoic acid | decreases expression | 1 |
| ferrous chloride | decreases expression | 1 |
| aflatoxin B2 | decreases methylation | 1 |
| nickel sulfate | decreases expression | 1 |
| ceric oxide | decreases expression | 1 |
| 1-nitropyrene | decreases expression | 1 |
| cobalt oxide | decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| entinostat | increases expression | 1 |
| 2,2’,4,4’,5-brominated diphenyl ether | increases expression | 1 |
| abrine | increases expression | 1 |
Cellosaurus cell lines
2 cell lines: 2 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B1HG | Abcam A-549 SECTM1 KO 2 | Cancer cell line | Male |
| CVCL_B2PZ | Abcam A-549 SECTM1 KO 1 | Cancer cell line | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.